Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers
Sponsor: Genentech, Inc.
Listed as NCT02640092, this PHASE1 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Genentech, Inc., it has been updated 16 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 11 earlier versions
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
-
Oct 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE1
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Nov 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .